Dr. Hendifar on PEGPH20 Survival Impact in High Hyaluronan Pancreatic Cancer

Andrew Hendifar, MD, MPH
Published: Wednesday, Jul 01, 2015



Andrew Hendifar, MD, MPH, Assistant Professor of Medicine at Cedars Sinai Medical Center and the David Geffen School of Medicine, discusses the use of a PEGylated form of rHuPH20 (PEGPH20) added to nab-paclitaxel/gemcitabine for pancreatic cancer patients with high levels of hyaluronan (HA).

In a phase I study investigating PEGPH20 with chemotherapy in stage IV patients, PEGPH20 didn’t have a statistically significant impact on progression-free survival or response rates in the overall population. However, when the 146-patient population was stratified to hyaluronan content, patients with high HA that had received PEGPH20 had nine months PFS compared to 4.5 months for those who did not receive PEGH20, said Hendifar.

<<< View more from the 2015 World GI Congress



Andrew Hendifar, MD, MPH, Assistant Professor of Medicine at Cedars Sinai Medical Center and the David Geffen School of Medicine, discusses the use of a PEGylated form of rHuPH20 (PEGPH20) added to nab-paclitaxel/gemcitabine for pancreatic cancer patients with high levels of hyaluronan (HA).

In a phase I study investigating PEGPH20 with chemotherapy in stage IV patients, PEGPH20 didn’t have a statistically significant impact on progression-free survival or response rates in the overall population. However, when the 146-patient population was stratified to hyaluronan content, patients with high HA that had received PEGPH20 had nine months PFS compared to 4.5 months for those who did not receive PEGH20, said Hendifar.

<<< View more from the 2015 World GI Congress




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Integrating Novel Targeted Treatment Strategies to Advance Pancreatic Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x